The Experts below are selected from a list of 141 Experts worldwide ranked by ideXlab platform
Magnus Grabe - One of the best experts on this subject based on the ideXlab platform.
-
impact of Cernitin on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
Phytomedicine Plus, 2021Co-Authors: Sophie Chabot, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Peranders Abrahamsson, Magnus GrabeAbstract:Abstract Background Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men.
-
the effects of Cernitin on inflammatory parameters and benign prostatic hyperplasia an in vitro study
Phytotherapy Research, 2019Co-Authors: Nishtman Dizeyi, Lena Ramnemark, Magnus Grabe, Ingrid Yao Mattisson, Peranders AbrahamssonAbstract:The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p <.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p <.001) and stromal cells (p <.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells. (Less)
Peranders Abrahamsson - One of the best experts on this subject based on the ideXlab platform.
-
impact of Cernitin on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
Phytomedicine Plus, 2021Co-Authors: Sophie Chabot, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Peranders Abrahamsson, Magnus GrabeAbstract:Abstract Background Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men.
-
the effects of Cernitin on inflammatory parameters and benign prostatic hyperplasia an in vitro study
Phytotherapy Research, 2019Co-Authors: Nishtman Dizeyi, Lena Ramnemark, Magnus Grabe, Ingrid Yao Mattisson, Peranders AbrahamssonAbstract:The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p <.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p <.001) and stromal cells (p <.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells. (Less)
Nishtman Dizeyi - One of the best experts on this subject based on the ideXlab platform.
-
impact of Cernitin on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
Phytomedicine Plus, 2021Co-Authors: Sophie Chabot, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Peranders Abrahamsson, Magnus GrabeAbstract:Abstract Background Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men.
-
the effects of Cernitin on inflammatory parameters and benign prostatic hyperplasia an in vitro study
Phytotherapy Research, 2019Co-Authors: Nishtman Dizeyi, Lena Ramnemark, Magnus Grabe, Ingrid Yao Mattisson, Peranders AbrahamssonAbstract:The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p <.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p <.001) and stromal cells (p <.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells. (Less)
Lena Ramnemark - One of the best experts on this subject based on the ideXlab platform.
-
impact of Cernitin on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
Phytomedicine Plus, 2021Co-Authors: Sophie Chabot, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Peranders Abrahamsson, Magnus GrabeAbstract:Abstract Background Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men.
-
the effects of Cernitin on inflammatory parameters and benign prostatic hyperplasia an in vitro study
Phytotherapy Research, 2019Co-Authors: Nishtman Dizeyi, Lena Ramnemark, Magnus Grabe, Ingrid Yao Mattisson, Peranders AbrahamssonAbstract:The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p <.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p <.001) and stromal cells (p <.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells. (Less)
J. Gieldanowski - One of the best experts on this subject based on the ideXlab platform.
-
The influence of pollen extracts (Cernitin GBX and Cernitin T60) on allergic reactions
Phytotherapy Research, 1992Co-Authors: L. Samochowiec, T. Dutkiewicz, J. Wójcicki, J. GieldanowskiAbstract:The influence of pollen extracts (Cernitin GBX and Cernitin T60) on some allergic reactions in animals and on the degranulation of mast cells and liberation of histamine has been studied. It was found that the Cernitins possess antiallergic properties in vivo and in vitro. Both pollen preparations were able to inhibit the degranulation of mastocytes and histamine release from these cells. The results indicate that antiallergic properties of the Cernitins might be dependent on their interaction with the mastocyte.
-
General immunological properties of fatsoluble (Cernitin GBX) and water-soluble (Cernitin T60) pollen extracts
Phytotherapy Research, 1991Co-Authors: L. Samochowiec, J. Gieldanowski, J. WójcickiAbstract:The immunological properties of fat-soluble (Cernitin GBX) and water-soluble (Cernitin T60) pollen extracts were examined in vivo and in vitro. For investigations in vitro we used the water-soluble pollen extract (T60), and in vivo the fat-soluble form (GBX). The aim of the in vivo experiments was to evaluate their effect on IgG antibody production, their capability of rosette formation (E-RFC) and cell indicating IgM-plaqueforming cells (PFC) hemolysins. Also observations were made on the effect of the pollen extract on graft vs host reaction, the transplantation barrier and delayed hypersensitivity in relation to sheep red blood cells (SRBC). Its assumed effect on phagocytosis and blastic transformation was assessed in vitro. In both in vivo and in vitro systems the influence of T60 and GBX preparations on the population of T- and B-cells was tested. A relationship was revealed between immunological activity and the evaluated Cernitins. Both the Cernitins examined demonstrated moderate immunoregulatory properties, but the immunosuppressive component was predominant.